1. Home
  2. RIGL vs FPH Comparison

RIGL vs FPH Comparison

Compare RIGL & FPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • FPH
  • Stock Information
  • Founded
  • RIGL 1996
  • FPH 2009
  • Country
  • RIGL United States
  • FPH United States
  • Employees
  • RIGL N/A
  • FPH N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • FPH Real Estate
  • Sector
  • RIGL Health Care
  • FPH Finance
  • Exchange
  • RIGL Nasdaq
  • FPH Nasdaq
  • Market Cap
  • RIGL 335.5M
  • FPH 390.0M
  • IPO Year
  • RIGL 2000
  • FPH 2017
  • Fundamental
  • Price
  • RIGL $38.85
  • FPH $5.68
  • Analyst Decision
  • RIGL Buy
  • FPH
  • Analyst Count
  • RIGL 5
  • FPH 0
  • Target Price
  • RIGL $38.20
  • FPH N/A
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • FPH 150.3K
  • Earning Date
  • RIGL 08-05-2025
  • FPH 10-16-2025
  • Dividend Yield
  • RIGL N/A
  • FPH N/A
  • EPS Growth
  • RIGL N/A
  • FPH 46.82
  • EPS
  • RIGL 5.43
  • FPH 1.08
  • Revenue
  • RIGL $267,921,000.00
  • FPH $197,429,000.00
  • Revenue This Year
  • RIGL $59.93
  • FPH N/A
  • Revenue Next Year
  • RIGL N/A
  • FPH N/A
  • P/E Ratio
  • RIGL $7.15
  • FPH $5.28
  • Revenue Growth
  • RIGL 105.62
  • FPH N/A
  • 52 Week Low
  • RIGL $12.66
  • FPH $3.10
  • 52 Week High
  • RIGL $43.72
  • FPH $6.71
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • FPH 56.60
  • Support Level
  • RIGL $39.00
  • FPH $5.51
  • Resistance Level
  • RIGL $42.08
  • FPH $5.77
  • Average True Range (ATR)
  • RIGL 2.32
  • FPH 0.14
  • MACD
  • RIGL -0.37
  • FPH 0.04
  • Stochastic Oscillator
  • RIGL 53.26
  • FPH 95.83

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About FPH Five Point Holdings LLC

Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its three reportable segments are Valencia, San Francisco, and Great Park. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.

Share on Social Networks: